Skip to contentpdufa.bio

BP-205 (orexin-2 agonist)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

BP-205 (orexin-2 agonist) is a Harmony Biosciences Holdings, Inc. program. Its next catalyst is a Readout in Q1 2027.

HRMY catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Harmony Biosciences Holdings, Inc. (HRMY). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q1 2027HRMY

Questions

When is BP-205 (orexin-2 agonist)'s next FDA decision or readout?

The next tracked catalyst for BP-205 (orexin-2 agonist) is a Readout in Q1 2027.

What happened at BP-205 (orexin-2 agonist)'s most recent FDA decision?

No FDA decision for BP-205 (orexin-2 agonist) is in our archive yet.

Who makes BP-205 (orexin-2 agonist)?

Harmony Biosciences Holdings, Inc. (HRMY).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.